Introduction {#s1}
============

Tuberculosis (TB) remains as one of the most common infectious disease in developing countries (Nasiri et al., [@B37]). In 2012, \~8.6 million people developed TB and 1.3 million died from the disease (Organization, [@B40]). TB is an important health problem, and this issue has become even more as a result of increasing number of drug resistant strains (Shamaei et al., [@B48]). There is not a complete data about first-line anti-tubercular drug resistance of *Mycobacterium tuberculosis* in Iran, one of the eastern Mediterranean countries locating between Azerbaijan and Armenia and high-TB burden countries (such as Afghanistan and Pakistan). Since 1996, when the national TB control programs established in Iran, TB incidence has been declining from 34 per 100,000 to 21 per 100,000 cases in 2011(Organization, [@B39]). Knowledge of geographic variations is essential for monitoring of antibiotic resistance within a defined population of patients infected with *M. tuberculosis* (Bahrmand et al., [@B8]). Isoniazid (INH), rifampin (RIF), streptomycin (SM), and ethambotol (EMB) are first-line chemotherapeutic drugs used in TB therapy (Mohammadi et al., [@B33]). Resistant to at least INH and RIF, is of great concern, because it requires the use of second-line drugs that are difficult to procure and are much more toxic and expensive than the first line regimen (Merza et al., [@B26]). Based on national wide survey conducted in 1999, among all *M. tuberculosis* isolates tested for drug susceptibility, 10.9% were resistant to = 1 anti-TB drug, and 6.7% were resistant to both INH and RIF (Organization, [@B38]). It has been proved that patients infected with strains resistant to RIF will experience a higher failure rate with short-course 6 months chemotherapy (Shamaei et al., [@B48]). Together with delayed diagnosis and lack or inadequacy of TB control programs, the emergence of MDR *M. tuberculosis* has complicated the epidemiology of TB (Yang et al., [@B61]). Although a number of original articles from different regions of Iran have been published in recent years, there has not been a systematic review of these data. Therefore, the aim of this study was to summarize reports on first-line anti-tubercular drug resistance of *M. tuberculosis* in Iran.

Materials and methods {#s2}
=====================

Literature search
-----------------

"*Mycobacterium tuberculosis* susceptibility," "*Mycobacterium tuberculosis* resistant," "*M. tuberculosis* susceptibility," and "*M. tuberculosis* resistant" and Iran were searched with special strategies in PubMed and Google Scholar engines. Three Persian scientific search engines "Scientific Information Database," "IranMedex," and "MagIran" were searched as well. Reference articles were explored. Both studies published in English and Persian were included. Gray literature and Abstracts of articles which published in congress were not explored. Search strategies were followed until 30th November 2014.

Inclusion criteria
------------------

We sought any articles of antimicrobial susceptibility testing of *M. tuberculosis* isolates. In addition, the bibliography of each article were reviewed to identify additional relevant articles. Among English and Persian articles found with mentioned strategies, those with the following features were included in the study: (1) Full text was available. (2) An original article was performed. (3) Susceptibility data for at least one anti- tubercular drug was available. (4) The laboratory method was used.

Exclusion criteria
------------------

Studies with at least one of the following aspects were excluded: (1) Studies that were not relevant. (2) Articles with only available abstracts (without full text). (3) Studies that did not use laboratory methods (using patients records). (4) Articles that use of second line of antimicrobial drug resistance. (5) Articles that were review. (6) Articles which contain no eligible data. (7) Case series reports. (8) Articles that sample size is too small (*N* \< 10).

Data collection
---------------

At this stage, articles with the following features were excluded as well: (1) Any articles were published both in English and Persian. (In these cases, the article published with more detailed results was chosen). (2) Duplicate publications. For all studies, we extracted the following data from the original publications. Literature identification and data extraction was performed by two researchers independently. Quality assessment of methodological sections and results of included articles was performed by use of STROBE checklist (<http://www.equator-network.org>).

Results {#s3}
=======

A total of 15,979 articles were achieved by literature search using different combination of key terms from the databases (Figure [1](#F1){ref-type="fig"}). After exclusion based on title not relevant and duplicates, 74 articles were retrieved for detailed full-text evaluation. Finally 52 studies, 24 in English, and 28 in Persian, addressing the prevalence of drug resistance TB were included (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). The original articles were performed in different places of Iran. Most studies were conducted in Tehran (*n* = 25; Bahrmand et al., [@B9]; Mohammadi et al., [@B33]; Seyed-Davood Mansoori et al., [@B47]; Masjedi et al., [@B24]; Mirsaeidi et al., [@B27]; Mohammadzadeh et al., [@B34]; Farnia et al., [@B15],[@B16]; Shamaei et al., [@B48]; Dinmohammadi et al., [@B13]; Merza et al., [@B26]; Ostadzadeh et al., [@B41]; Sheikholslami et al., [@B50]; Taghavi et al., [@B52]; Tasbiti et al., [@B56]; Derakhshani Nezhad et al., [@B12]; Marjani et al., [@B23]; Mohammadi, [@B32]; Tahmasebi et al., [@B55]; Bahrami et al., [@B7]; Ali et al., [@B2]; Nasiri et al., [@B37]; Sheikh Ghomi et al., [@B49]; Varahram et al., [@B58]; Velayati et al., [@B60]) and Tabriz (*n* = 8; Hassan Heidarnejad and Nagili, [@B18]; Moadab and Rafi, [@B28]; Varshochi et al., [@B59]; Asgharzadeh et al., [@B3], [@B4]; Rafi et al., [@B43]; Roshdi and Moadab, [@B45]; Zamanlou et al., [@B63]). Other studies were performed in Khorasan (*n* = 3; Namaei et al., [@B36]; Velayati et al., [@B60]; Sani et al., [@B46]), Ardebil (*n* = 1; Velayati et al., [@B60]), Isfahan (*n* = 3; Moniri, [@B35]; Nasiri et al., [@B37]; Velayati et al., [@B60]), Mazandaran (*n* = 3; Pourhajibagher et al., [@B42]; Babamahmoodi et al., [@B6]; Velayati et al., [@B60]), Gilan (*n* = 1; Velayati et al., [@B60]), Hamadan (*n* = 1; Velayati et al., [@B60]), Kerman(*n* = 1; Velayati et al., [@B60]), Kurdistan(*n* = 1; Velayati et al., [@B60]), Yazd (*n* = 1; Velayati et al., [@B60]), Qazvin (*n* = 1; Velayati et al., [@B60]), Kermanshah (*n* = 4; Izadi et al., [@B19]; Nasiri et al., [@B37]; Velayati et al., [@B60]; Mohajeri et al., [@B30]), Golestan (*n* = 3; Javid et al., [@B20]; Livani et al., [@B22]; Velayati et al., [@B60]), Markazi (*n* = 3; Farazi et al., [@B14]; Taherahmadi et al., [@B53]; Velayati et al., [@B60]), Lorestan (*n* = 1; Velayati et al., [@B60]), Khuzestan (*n* = 2; Khosravi et al., [@B21]; Velayati et al., [@B60]), Sistan va Baluchistan (*n* = 5; Bostanabad et al., [@B10]; Bahrmand et al., [@B8]; Haeili et al., [@B17]; Nasiri et al., [@B37]; Velayati et al., [@B60]), Qom (*n* = 1; Velayati et al., [@B60]), Fars (*n* = 1; Velayati et al., [@B60]), Hormozgan (*n* = 2; Nasiri et al., [@B37]; Velayati et al., [@B60]), and Semnan (*n* = 1; Velayati et al., [@B60]). A study which was conducted by Velayati et al. ([@B60]), in years 2010--2011, has been investigated drug resistant in various places in Iran (Tehran, Sistan ba Balochestan, Khozestan, Khorasan, Ardebil, Qom, Golestan, Isfahan, Gilan, Fars, Hormozgan, Mazandaran, Semnan, Lorestan, Hamedan, Kerman, Kordestan, Kermanshah, Markazi, Yazd, and Qazvin (Velayati et al., [@B60]), but we identified it as 1 study in search flow diagram, it was considered for Nasiri et al. study too (Nasiri et al., [@B37]). In Isfahan, 4 surveys were performed but in one of them (Tavakoli et al.) only abstract was available, and it was excluded from total records. One study which was conducted by Moaddab et al. ([@B29]) that did not note the location. One study has been done in Tehran and Zabol (Zakerbostanabad et al., [@B62]). One study has been conducted by Haeili et al. ([@B17]) in Tehran, Alborz, Sistan va Blochestan, Hormozgan, and Kermanshah. Another study had been done in Tehran-Arak by Taheri et al. ([@B54]). The reference method for determining drug resistance of *M. tuberculosis* was agar proportion. Using this method, the mean of resistance to INH, RIF, SM and EM in Iran was 20, 18, 18%, and to EM is 12%, respectively. Despite the reference method for susceptibility test is agar proportion (Rieder et al., [@B44]), the method that was used in most of the cities were PCR. For this reason, we determine the mean of resistance to INH and RIF in different geographical regions based on this method too. If Iran is divided into 8 geographical regions (Table [3](#T3){ref-type="table"}), the mean of resistance to INH in Northern provinces of country was 5%, and maximum resistance was seen in Golestan and the minimum resistance was belonged to Gilan province. The mean of resistance to RIF was 4%, and the maximum and minimum resistance was seen in Gilan and Mazandaran, respectively. The mean of resistance to INH and RIF in Southern provinces of Iran was 6.45 and 10%, respectively. The mean of resistance to INH in Western provinces of country was 5%, and the maximum resistance belonged to Kordestan and minimum resistance was seen in Lorestan. The mean of resistance to RIF was 11%, and the highest and lowest resistance was seen in Lorestan and Kordestan. The mean of resistance to INH and RIF in Northwest provinces of Iran was 6.5 and 3%, respectively. The mean of resistance to INH in central provinces of country was 9%, and maximum resistance belonged to Markazi while minimum resistance belong to Yazd that no resistance has been seen. The mean of resistance to RIF was 10%, and the highest and lowest level of resistance was seen in Markazi and Qom. One of the provinces of central regions is Isfahan. In Isfahan the mean of resistance to INH based on agar proportion was 12.6% which was similar to PCR method (12%), but mean of resistance to RIF based on agar proportion was 26%, that was higher than PCR method (7%). In Markazi provinces, the mean of resistance to INH, based on reference method was 2.6% that was lower than PCR; there was the same result about RIF too. In Southwest of Iran, resistance to INH and RIF was 6 and 5%, respectively. The mean of resistance to INH and RIF in Northeast provinces of Iran was 4%. In Southeast provinces of Iran such as Sistan- Blochestan and Kerman, the mean of resistance to INH and RIF was 4.4 and 9% based on PCR method. Because the most of method that use in Sistan- Blochestan was agar proportion, we calculate the mean of resistance to INH and RIF based on the mentioned method, (INH 20% and RIF 12%). Due to the large number of studies in Tehran and Tabriz, these provinces were examined separately. The most common laboratory method that used was agar proportion in Tehran. The average prevalence of resistant against INH in Tehran was 26%, RIF 23%, SM 22.5%, and EMB 16% by agar proportion method. In general, resistance to INH was more common than RIF, SM and EMB in Tehran. The average prevalence of resistant against INH in Tabriz was 15%, RIF 5%, SM 19%, and EMB 2.43% by agar proportion. The highest resistance to first-line drugs was seen in Tehran. Most studies about two drug resistances were conducted in Tehran by proportional method on INH and RIF. The mean of resistance to INH and RIF in Tehran was 22% by proportional method. The mean of resistance to INH and RIF in IRAN was 15% by this method. Due to the limited number of studies on other two drug resistance, the results are given only in Table [2](#T2){ref-type="table"}. Most studies on three drug resistance were conducted on INH, RIF and SM. The mean of resistance to these three drugs was 4% using proportional method. The mean of resistance to all first line drugs in IRAN was 3.57% by this method.

![**Flow diagram of study identification**.](fmicb-07-01139-g0001){#F1}

###### 

**Summary of studies on resistance to a single drug among Mycobacterium tuberculosis isolates in Iran**.

  **Study**                                                  **Resistance to a single drug**                                                                                                                                                                                 
  ---------------------------------------------------------- --------------------------------------- ------------ -------------------------------------------- ------ ----------------------------------------- ---------- --------- ---------- -------- ---------- -------- ----------
                                                                                                                                                                      *N*                                       \%         *N*       \%         *N*      \%         *N*      \%
  Ardebil                                                    Velayati et al., [@B60]                 2010--2011   PCR(a)                                       65     2                                         3          4         6          ...      ...        ...      ...
  Fars                                                       Velayati et al., [@B60]                 2010--2011   PCR(a)                                       40     2                                         5          5         12.5       ...      ...        ...      ...
  Gilan                                                      Velayati et al., [@B60]                 2010--2011   PCR(a)                                       39     1                                         2.5        2         5          ...      ...        ...      ...
  Golestan                                                   Javid et al., [@B20]                    2008         PCR(b)                                       87     6                                         7          4         5          ...      ...        ...      ...
                                                                                                                  Agar proportion                              45     4                                         9          6         13         ...      ...        ...      ...
                                                             Livani et al., [@B22]                   ...          MGIT                                         148    26                                        18         5         3          ...      ...        ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       47     3                                         6          2         4          ...      ...        ...      ...
  Qom                                                        Velayati et al., [@B60]                 2010--2011   PCR(a)                                       61     3                                         5          3         5          ...      ...        ...      ...
  Hormozgan                                                  Velayati et al., [@B60]                 2010--2011   PCR(a)                                       38     3                                         8          3         8          ...      ...        ...      ...
                                                             Nasiri et al., [@B37]                   2010--2012   Agar proportion                              48     3                                         6          2         4          4        8          2        4
  Hamedan                                                    Velayati et al., [@B60]                 2010--2011   PCR(a)                                       21     1                                         5          2         10         ...      ...        ...      ...
  Isfahan                                                    Velayati et al., [@B60]                 2010--2011   PCR(a)                                       42     5                                         12         3         7          ...      ...        ...      ...
                                                             Nasiri et al., [@B37]                   2010--2012   Agar proportion                              45     2                                         7          2         9          1        2          0        0
                                                             Moniri, [@B35]                          1998--2009   Agar proportion                              94     17                                        18         41        44         14       15         3        3
  Khorasan                                                   Namaei et al., [@B36]                   2001--2002   indirect proportion                          105    1                                         1          ...       ...        27       26         ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       117    10                                        8.5        9         8          ...      ...        ...      ...
                                                             Sani et al., [@B46]                     2012--2013   Agar proportion                              100    7                                         7          7         7          9        9          3        3
  Kermanshah                                                 Izadi et al., [@B19]                    2006--2008   Agar proportion                              14     8                                         57         6         43         ...      ...        ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       16     1                                         6          2         12.5       ...      ...        ...      ...
                                                             Nasiri et al., [@B37]                   2010--2012   Agar proportion                              15     4                                         26.6       3         20         3        20         3        20
                                                             Mohajeri et al., [@B30]                 2011--2012   Agar proportion                              112    18                                        16         16        14         25       22         15       13
  Kermanshah                                                 Mohajeri et al., [@B31]                 2011--2013   Agar proportion                              125    ...                                       ...        35        28         ...      ...        ...      ...
  Khozestan                                                  Khosravi et al., [@B21]                 2001         PCR(c)                                       80     5                                         6          6         7.5        ...      ...        ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       119    7                                         6          3         2.5        ...      ...        ...      ...
  Kerman                                                     Velayati et al., [@B60]                 2010--2011   PCR(a)                                       24     1                                         4          3         12.5       ...      ...        ...      ...
  Kordestan                                                  Velayati et al., [@B60]                 2010--2011   PCR(a)                                       16     2                                         12.5       0         0          ...      ...        ...      ...
  Lorestan                                                   Velayati et al., [@B60]                 2010--2011   PCR(a)                                       24     0                                         0          5         21         ...      ...        ...      ...
  Mazandaran                                                 Pourhajibagher et al., [@B42]           2010--2011   PCR(d)                                       59     4(use of katG gene) 3(use of inhA gene)   7 5        1         2          ...      ...        ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       26     1                                         4          1         4          ...      ...        ...      ...
                                                             Babamahmoodi et al., [@B6]              ...          LPA(e)                                       54     2                                         4          3         5.5        4        7          ...      ...
  Markazi                                                    Taherahmadi et al., [@B53]              ...          Agar proportion PCR-RFLP (f)                 60     ...                                       ...        ...       ...        ...      ...        43 19    72 32
                                                             Farazi et al., [@B14]                   2011--2012   Agar proportion                              115    3                                         3          2         2          3        3          8        7
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       15     3                                         20         3         20         ...      ...        ...      ...
  Qazvin                                                     Velayati et al., [@B60]                 2010--2011   PCR(a)                                       10     1                                         10         0         0          ...      ...        ...      ...
  Semnan                                                     Velayati et al., [@B60]                 2010--2011   PCR(a)                                       21     0                                         0          0         0          ...      ...        ...      ...
                                                             Zakerbostanabad et al., [@B62]          2005--2006   Agar proportion                              91     28                                        31         4         4          23       25         8        9
  Sistan va Balochestan                                      Bahrmand et al., [@B8]                  2005--2006   Agar proportion                              286    ...                                       ...        78        27         ...      ...        ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       165    8                                         5          10        6          ...      ...        ...      ...
                                                             Nasiri et al., [@B37]                   2010--2012   Agar proportion                              59     5                                         8          3         5          8        13.5       3        5
  Tehran                                                     Ostadzadeh et al., [@B41]               ...          Agar proportion                              50     ...                                       ...        25        50         ...      ...        ...      ...
                                                             Farnia et al., [@B15]                   ...          Agar proportion MGMT Both of them            60     0 0 30                                    0 0 50     0 0 30    0 0 50     4 3 29   7 5 48     3 5 28   5 8 47
                                                             Sheikholslami et al., [@B50]            ...          Agar proportion PCR-SSCP(g)                  74     17 10                                     23 13.5    7 4       9 5        ...      ...        ...      ...
                                                             Seyed-Davood Mansoori et al., [@B47]    1996--2000   Agar proportion                              273    76                                        28         50        18.5       50       18.5       28       10
                                                             Bahrmand et al., [@B9]                  1998--1999   Agar proportion                              563    35                                        6          25        4          55       10         17       3
                                                             Mohammadi et al., [@B33]                1999--2000   MGIT Direct MGIT in Direct Agar proportion   15     10 10 7                                   67 67 47   11 11 8   73 73 53   5 6 7    33 40 47   5 5 5    33 33 33
                                                             Dinmohammadi et al., [@B13]             1999--2008   Agar proportion                              90     52                                        58         ...       ...        ...      ...        ...      ...
                                                             Shamaei et al., [@B48]                  2000--2003   Agar proportion                              548    152                                       28         119       22         184      34         75       14
                                                             Merza et al., [@B26]                    2000--2005   Agar proportion                              1742   414                                       24         307       18         478      27         207      12
                                                             Mirsaeidi et al., [@B27]                2003--2004   Agar proportion                              264    93                                        35         52        20         96       36         35       13
                                                             Marjani et al., [@B23]                  2003--2008   Agar proportion                              554    81                                        15         27        5          116      21         22       4
                                                             Varahram et al., [@B58]                 2003--2011   Agar proportion and Allele specific PCR      4825   296                                       6          ...       ...        ...      ...        ...      ...
                                                             Farnia et al., [@B16]                   2006--2007   Agar proportion                              258    9                                         3          3         1          7        3          1        0.4
                                                             Mohammadi, [@B32]                       2006--2008   Agar proportion MAS-PCR(h)                   90     ...                                       ...        37 29     41 32      ...      ...        ...      ...
                                                             Tasbiti et al., [@B56]                  2006--2009   Agar proportion                              1027   116                                       11         110       11         232      23         104      10
                                                             Taghavi et al., [@B52]                  2008--2009   Agar proportion MAS-PCR(i)                   96     56 43                                     58 45                           ...      ...        ...      ...
                                                                                                                                                                                                                                                                             
                                                             Ali et al., [@B2]                       2009--2011   Agar proportion PCR-SSCP                     103    12 5                                      12 5       9 4       9 4        ...      ...        ...      ...
                                                             Velayati et al., [@B60]                 2010--2011   PCR(a)                                       324    20                                        6          26        8                                       
                                                                                                                                                                                                                                                                             
                                                             Derakhshani Nezhad et al., [@B12]       2010--2011   Agar proportion Allele-specific PCR          106    ...                                       ...        ...       ...        ...      ...        36 13    34 28
                                                             Tahmasebi et al., [@B55]                2010--2011   Agar proportion                              97     68                                        70         63        65         28       29         47       48
                                                             Bahrami et al., [@B7]                   2010--2012   Agar proportion                              176    ...                                       ...        ...       ...        ...      ...        48       27
                                                             Nasiri et al., [@B37]                   2010--2012   Agar proportion                              85     6                                         7          7         8          14       16         6        7
                                                             Sheikh Ghomi et al., [@B49]             2012--2013   Agar proportion and Multiplex PCR            83     35                                        42         47        56         ...      ...        ...      ...
  Tabriz                                                     Zamanlou et al., [@B63]                 2005--2007   Agar proportion                              50     25                                        50         ...       ...        ...      ...        ...      ...
                                                             Rafi et al., [@B43]                     ...          Agar proportion                              90     6                                         7          3         3          17       19         ...      ...
                                                             Moadab and Rafi, [@B28]                 1999--2003   Agar proportion                              90     7                                         8          2         2          17       19         ...      ...
                                                             Asgharzadeh et al., [@B3]               ...          Agar proportion MAS-PCR(j)                   120    13                                        11         12        10         27       22.5       4 10     3 8
                                                             Roshdi and Moadab, [@B45]               ...          Agar proportion                              103    2                                         2          0         0          8        8          0        0
                                                             Varshochi et al., [@B59]                2003--2004   Agar proportion                              90     20                                        22         9         10         28       31         5        5.5
                                                             Hassan Heidarnejad and Nagili, [@B18]   ...          Agar proportion                              155    12                                        8          1         1          20       13         0        0
                                                             Asgharzadeh et al., [@B4]               ...          Agar proportion                              120    13                                        11         12        10         27       22.5       4        3
  Yazd                                                       Velayati et al., [@B60]                 2010--2011   PCR(a)                                       12     0                                         0          1         8          ...      ...        ...      ...
  Tehran-Arak                                                Taheri et al., [@B54]                   ...          Agar proportion                              40     ...                                       ...        20        50         ...      ...        ...      ...
  Tehran--Alborz-Sistan va Blochestan-Hormozgan-Kermanshah   Haeili et al., [@B17]                   2010--2012   Agar proportion                              291    4                                         1          2         1          21       7          2        1
  Tehran-Zabol-Kermanshah-Mashad-Tabriz                      Bostanabad et al., [@B11]               2007--2008   Agar proportion                              163    42                                        26         38        23         38       23         12       7
  Unknown                                                    Moaddab et al., [@B29]                  ...          Agar proportion and MIC                      50     25                                        50         ...       ...        ...      ...        ...      ...

*(a): Multiplex-PCR assay for detection of mutations in RRDR(Rifampin resistance determinant region), and PCR assay for detection of mutations in IRDR (Isoniazid resistance determinant region) of katG, inhA*.

*(b): PCR assay for detection of mutations in RRDR of rpoB and IRDRof katG and inhA*.

*(c): PCR assay for detection of mutations in RRDR of rpoB and IRDR of katG*.

*(d): PCR assay for detection of mutations in RRDR of rpoB and IRDR of katG and inhA*.

*(e): Line Probe Assay*.

*(f): PCR-RFLP assay for detection of mutations in ERDR (Ethambotol resistance determinant region) of embB*.

*(g): PCR-SSCP assay for detection of mutations in RRDR of rpoB, ahpC and IRDR of katG, inhA*.

*(h): Mass-PCR assay for detection of mutations in RRDR of rpoB*.

*(i): Mass-PCR assay for detection of mutations in IRDR of katG*.

*(j): MAS-PCR assay for detection of mutations in ERDR of embB*.

*MGIT, Mycobacterium growth indicator tube; MIC, minimum inhibitory concentration; MGMT, malachite green microtube*.

###### 

**Summary multiple drug resistance of included studies**.

  **Author**                                **location**                                              **Method**            **INH,RIF**   **INH,EMB**   **INH,SM**   **RIF,EMB**   **EMB,SM**   **RIF,SM**   **RIF,EMB,SM**   **INH,EMB,SM**   **INH,RIF,EMB**   **INH,RIF,SM**   **INH,RIF,SM,EMB**                                                         
  ----------------------------------------- --------------------------------------------------------- --------------------- ------------- ------------- ------------ ------------- ------------ ------------ ---------------- ---------------- ----------------- ---------------- -------------------- ----- ---- --- ---- ----- ---- ----- ---- ----- ----- ----
  Velayati et al., [@B60]                   Ardebil                                                   PCR                   4             6                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Fars                                                      PCR                   5             12.5                                                                                                                                                                                                               
  Velayati et al., [@B60]                   Gilan                                                     PCR                   3             8                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Golestan                                                  PCR                   2             4                                                                                                                                                                                                                  
  Javid et al., [@B20]                      Golestan                                                  ProportionPCR         4 2           9 2                                                                                                                                                                                                                
  Livani et al., [@B22]                     Golestan                                                  MGIT                  5             3                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Ghom                                                      PCR                   4             6.5                                                                                                                                                                                                                
  Velayati et al., [@B60]                   Hormozgan                                                 PCR                   3             8                                                                                                                                                                                                                  
  Nasiri et al., [@B37]                     Hormozgan                                                 Proportion            2             4                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Hamedan                                                   PCR                   0             0                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Isfahan                                                   PCR                   2             5                                                                                                                                                                                                                  
  Moniri, [@B35]                            Isfahan                                                   Proportion            16            17                                       9            10           2                2                                                   12                   13                                   8    8.5   1     1
  Nasiri et al., [@B37]                     Isfahan                                                   Proportion            2             4                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Khorasan                                                  PCR                   2             2                                                                                                                                                                                                                  
  Namaei et al., [@B36]                     Khorasan                                                  Proportion                                                                                                                               1                 1                                                    1    1                                 
  Sani et al., [@B46]                       Khorasan                                                  Proportion            4             4                                        3            3                                                                                 4                    4                                               2     2
  Velayati et al., [@B60]                   Kermanshah                                                PCR                   1             6                                                                                                                                                                                                                  
  Izadi et al., [@B19]                      Kermanshah                                                Proportion            5             36                                                                                                                                                                                                                 
  Nasiri et al., [@B37]                     Kermanshah                                                Proportion            3             20                                                                                                                                                                                                                 
  Mohajeri et al., [@B30]                   Kermanshah                                                Proportion            16            14                                                                                                                                                                                                                 
  Velayati et al., [@B60]                   Khozestan                                                 PCR                   6             5                                                                                                                                                                                                                  
  Khosravi et al., [@B21]                   Khozestan                                                 Proportion            7             9                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Kerman                                                    PCR                   3             12.5                                                                                                                                                                                                               
  Velayati et al., [@B60]                   Kordestan                                                 PCR                   0             0                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Lorestan                                                  PCR                   0             0                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Mazandaran                                                PCR                   1             4                                                                                                                                                                                                                  
  Babamahmoodi et al., [@B6]                Mazandaran                                                LPA                   0             0                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Markazi                                                   PCR                   2             13                                                                                                                                                                                                                 
  Farazi et al., [@B14]                     Markazi                                                   Proportion            9             8                                                                                                                                                                                                            2     2
  Velayati et al., [@B60]                   Qazvin                                                    PCR                   2             20                                                                                                                                                                                                                 
  Velayati et al., [@B60]                   Semnan                                                    PCR                   0             0                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Sistan va Blochestan                                      PCR                   1             1                                                                                                                                                                                                                  
  Nasiri et al., [@B37]                     Sistan va Blochestan                                      Proportion            3             5                                                                                                                                                                                                                  
  Bahrmand et al., [@B8]                    Sistan va Blochestan                                      Proportion            37            13                                                                                                                                                                                                                 
  Velayati et al., [@B60]                   Tehran                                                    PCR                   32            10                                                                                                                                                                                                                 
  Tahmasebi et al., [@B55]                  Tehran                                                    Proportion            63            65                                                                                                                                                                                                                 
  Mohammadzadeh et al., [@B34]              Tehran                                                    Proportion            11            48                                                                                                                                                                                                                 
  Ostadzadeh et al., [@B41]                 Tehran                                                    Proportion            13            26                                                                                                                                                                                                                 
  Taghavi et al., [@B52]                    Tehran                                                    Proportion MAS-PCR    36 26         38 27                                                                                                                                                                                                              
  Masjedi et al., [@B24]                    Tehran                                                    Proportion                                                                                                                                                                                                                                       150   12
  Bahrami et al., [@B7]                     Tehran                                                    Proportion            10            6             12           7                                       19               11                                                                                                 8    4.5                    
  Shamaei et al., [@B48]                    Tehran                                                    Proportion            106           19                                                                                                                                                                                                                 
  Mirsaeidi et al., [@B27]                  Tehran                                                    Proportion            43            16            0            0             23           9            0                0                2                 1                4                    1.5   0    0   2    1     0    0     9    3     26    10
  Seyed-Davood Mansoori et al., [@B47]      Tehran                                                    Proportion            42            15.5          26           9.5           40           14.5         21               7.5              22                8                23                   8.5   17   6   21   7.5   21   7.5   22   8     17    6
  Bahrmand et al., [@B9]                    Tehran                                                    Proportion            3             0.5                                      4            1                                                                                 1                    0.1                       1    0.1              7     1
  Farnia et al., [@B15]                     Tehran                                                    MGMT                  8             19                                                                                                                                                                                                                 
  Nasiri et al., [@B37]                     Tehran                                                    Proportion            6             7                                                                                                                                                                                                                  
  Sheikholslami et al., [@B50]              Tehran                                                    Proportion PCR-SSCP   16 4          22 5                                                                                                                                                                                                               
  Merza et al., [@B26]                      Tehran                                                    Proportion            263           15                                                                                                                                                                                                                 
  Marjani et al., [@B23]                    Tehran                                                    Proportion            12            2                                                                                                                                                                                                                  
  Sheikh Ghomi et al., [@B49]               Tehran                                                    Proportion and PCR    30            36                                                                                                                                                                                                                 
  Imani Fooladi et al., Ali et al., [@B2]   Tehran                                                    Proportion PCR-SSCP   9 3           9 3                                                                                                                                                                                                                
  Rafi et al., [@B43]                       Tabriz                                                    Proportion            2             2                                                                                                                                                                                      1    1     3    3     2     2
  Moadab and Rafi, [@B28]                   Tabriz                                                    Proportion            1             1                                        6            7                                                                                                                     1    1     1    1     3    3     2     2
  Asgharzadeh et al., [@B3]                 Tabriz                                                    Proportion            1             1                                        5            4                                                                                                                     1    1                2    2     2     2
  Roshdi and Moadab, [@B45]                 Tabriz                                                    Proportion                                        1            1                                                                         1                 1                                                                          1    1     2     2
  Varshochi et al., [@B59]                  Tabriz                                                    Proportion                                                                                                                                                                                                                                       1     1
  Hassan Heidarnejad and Nagili, [@B18]     Tabriz                                                    Proportion                                        5            3                                                                                                                                                                                       
  Asgharzadeh et al., [@B4]                 Tabriz                                                    Proportion            6             5                                                                                                                                                                                                                  
  Velayati et al., [@B60]                   Yazd                                                      PCR                   0             0                                                                                                                                                                                                                  
  Haeili et al., [@B17]                     Tehran-Alborz Sistan va Blochestan Hormozgan Kermanshah   Proportion            15            5                                                                                                                                                                                                                  

###### 

**Different geographical regions of Iran**.

  **Region**   **Provinces**
  ------------ ------------------------------------------
  North        Golestan, Gilan, Mazandaran
  South        Fars, Hormozgan
  West         Kordestan, Kermanshah, Lorestan, Hamedan
  Center       Isfahan, Qom, Markazi, Yazd
  Northeast    Khorasan, Semnan
  Northwest    Ardebil, Ghazvin
  Southeast    Sistan-Blochestan, Kerman
  Southwest    Khozestan

Discussion {#s4}
==========

This review addressed the prevalence of first-line anti-tubercular drug resistance of *M. tuberculosis* in Iran. Various types of methods were used for determination of the susceptibility of *M. tuberclusis*: agar proportion (reference method), different types of PCR (PCR-RFLP, Real time PCR, PCR-SSCP, MAS-PCR, and Allele specific PCR), MGMT, and MGIT (direct and indirect). But most of them that used were agar proportion or PCR. In all the studies that use both of them, the results of reference method (agar proportion) had the highest of sensitivity and specificity (Javid et al., [@B20]; Sheikholslami et al., [@B50]; Derakhshani Nezhad et al., [@B12]; Mohammadi, [@B32]; Taherahmadi et al., [@B53]). In this study, evaluation of first-line anti-tubercular drug resistance in various provinces of Iran was based on PCR method that is not very accurate. It seems that the prevalence of drug resistance is higher than the results of studies that use mentioned method (PCR). As can be seen in the Table [1](#T1){ref-type="table"}, the highest resistance of *M. tuberculosis* to first line drugs was observed in Tehran, INH:26%, RIF:23%, SM:22.5%, and EMB:16%. This could be due to transferring of patients with treatment failure to referral Hospitals in Tehran. The other reason could be presence of different nations such as Afghan, Iraq and Pakistan in Tehran. Between 1996 to 2000, three studies have been conducted in Tehran, Mohammadi et al. ([@B33]), Bahrmand et al. ([@B9]), and Seyed-Davood Mansoori et al. ([@B47]) reported the resistance prevalence of 46.6, 6.2, and 28% to isoniazid, respectively. The reason of this difference could be due to small sample size in first study (Mohammadi et al., [@B33]). In Mohamadi et al. study, *M. tuberculosis* was isolated from referral patients that can be the reason of high resistance to isoniazid in this study. Two studies have been conducted in 2010--2011, in Velayati et al. ([@B60]) reports, the prevalence of isoniazid resistance was 6% and in Tahmasebi et al. ([@B55]) this level was 70.1%, that the reason of this difference could be used to strains that isolate from patients with treatment failure in second study. Over the years the increasing level of resistance to isoniazid might be due to incomplete treatment. The failure treatment can be for two reason, inappropriate drug prescribing and drug usage regularly and on time. This process has been seen about rifampin resistance. During 2000 and 2008, Shamaei et al. ([@B48]) and Merza et al. ([@B26]) reported the highest prevalence of rifampin resistance. These studies have been done in Masih daneshvari Hospital that is a referral hospital in Iran and most of the patients refer to this hospital due to treatment failure. As mentioned in results, high prevalence of resistance to INH (20%) and RIF (12%) was seen in Sistan va Blochestan due to vicinity of this province to Afghanistan and Pakistan. Rifampin and isoniazid resistance is a surrogate marker for MDR- *M. tuberculosis*. Most of studies reporting isoniazid and rifampin resistance were conducted in Tehran. These studies report the highest prevalence of resistance to INH and RIF (22%). In Masjedi et al. ([@B25]) study, among 77% Iranian and 23% afghan cases, 131 Iranian (65%), and 13 afghan cases (22%) were susceptible to all 4 drugs tested and 72 patients (28%) were MDR-TB case. Notably, 38 MDR-TB cases (52.7%) were isolated from afghan immigrants. Twenty patients (47%) had mono drug resistant strains (nine were INH, seven SM, three RF, and one EMB mono resistant) and 22 (52%) had combined resistance.

In Al-Akhali et al. ([@B1]) study that was performed in Yemen, the prevalence of resistance to any one of the four drugs was 9.8% in the new cases and 17.4% in the previously treated cases. The prevalence of MDR-TB, defined as TB cases excreting *M. tuberculosis* resistant at least to INH and RIF, was 3%. In Ayaz et al. ([@B5]) study that conducted in Pakistan, resistance to one or more of the first-line anti-TB drugs was noted in 23% of patients. The INH resistance was 9% in untreated and 28.5% in treated patients. Resistance to other first-line drugs was as follow: SM 17%, EMB 5%, and RIF 5%.

Some limitations of this systematic review should be considered for results interpretation. First, few studies have been conducted in our country about resistance of TB to first and second line-drugs. Second, the probable influence of age, sex, ethnicity, economic level, and life styles could not be analyzed due to the limited information obtained from the original articles. Third, most included studies were hospital-based rather than population based which makes the results more prone to potential selection bias. Because of the small number of studies particularly in other cities except Tehran, we cannot judge about the prevalence of resistance against first-line anti-tuberculosis drugs properly. However, in recent years, emergence and spread of MDR-TB threaten the TB control strategy. In many law-and middle-income countries, due to inadequate laboratory capacity, most of the patients with MDR-TB are not diagnosed. Treatment of these cases mostly failed and significant expenditure of health care resources is needed.

In conclusion, this systematic review summarized the prevalence and distribution of first-line anti-tubercular drug resistance of *M. tuberculosis* in Iran. Our results suggest effective strategies to minimize the acquired drug resistance, to control the transmission of resistance and improve the diagnosis measures for TB control in our country.

An important element in gaining control of this epidemic is developing an understanding of the molecular basis of resistance to the most important anti-tuberculosis drugs. Since the mechanism of action of rifampin is to inhibit mycobacterial transcription by targeting DNA-dependent RNA polymerase (Somoskovi et al., [@B51]), routine application of rapid molecular tests in the clinical management of drug-resistant tuberculosis is highly recommended.

On the other hand, INH is activated by the mycobacterial enzyme KatG, a multifunctional catalase-peroxidase that has other activities including peroxynitritase and NADH oxidase. Therefore, inhibition of both cell wall lipid, and nucleic acid synthesis by INH-NAD and INH-NAPD adducts together with respiratory inhibition by INH-derived NO can provides a potent antituberculosis cocktail. Some strategies such as developing agents that produce the isonicotinoyl radical, screening for molecules which increase mycobacterial levels of NAD+ or NADP+ for in co-administration use with INH, to designing of more drug-like molecules using the structure of INH-NAD adducts to inhibit specifically mycobacterial enzymes; and developing of mycobacterial enzyme inhibitors which can inactivate INH might be useful to control INH-TB resistance propagation (Timmins and Deretic, [@B57]).
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